



cancers



an Open Access Journal by MDPI

State-of-the-Art Mechanisms of Drug Resistance to Targeted Therapy in Cancers

Guest Editors:

Dr. Yan Li

The Centre for Biomedical and Chemical Sciences, School of Science, Faculty of Health and Environmental Sciences, Auckland University of Technology, Auckland 1010, New Zealand

Dr. Johnson Liu

Department of Pharmacology, School of Medical Sciences, University of New South Wales, Sydney, NSW 2052, Australia

Deadline for manuscript submissions:

25 November 2024

Message from the Guest Editors

Dear Colleagues,

Drug resistance is an overwhelming challenge in cancer treatment, particularly in the context of targeted therapies. Targeted therapies are designed to inhibit specific proteins or pathways that are critical for tumour growth and progression. Genetic alterations, bypass signalling, altered drug transport/metabolism, epigenetic changes, tumour heterogeneity, the tumour microenvironment, and adaptive evolution all contribute to tumour resistance.

It is crucial to note that these mechanisms can vary across different cancer types and even among individual patients. Additionally, cancer cells can employ multiple mechanisms simultaneously or develop new resistance mechanisms over time, further complicating treatment strategies. Overcoming drug resistance remains a significant area of research, and ongoing efforts are focused on identifying and targeting these mechanisms in order to develop novel therapeutic strategies and enhance cancer treatment outcomes.

This Special Issue will address subjects related to recent progress on mechanisms of drug resistance to targeted therapy in cancer therapy.

Dr. Yan Li
Guest Editor



mdpi.com/si/175562

Special Issue



cancers



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
X@Cancers_MDPI